L ow density lipoprotein (LDL) is the principal carrier of plasma cholesterol in humans, and LDL levels have been positively correlated with the development of atherosclerosis.
Apolipoprotein B (apo B) is the major protein species of LDL, but the elucidation of its structure has proven to be a most difficult task mainly because of its total insolubility in a delipidated form which may be related to high oxidation sensitivity. 1 While widely varying molecular weights for apo B have been reported in recent years, it is now thought to have a molecular weight in excess of 200.000. 2 ' 3 The LDL receptor present on the surface of mammalian cells binds certain plasma lipoproteins by recognizing sites which are present on apo B as well as on apo E. 4 ' 5 The binding of LDL to the LDL receptor initiates a series of events which has been called the LDL pathway. 6 ' 7 The LDL is taken into the cell where it is hydrolyzed in lysosomes. The released cholesterol inhibits endogenous cholesterol synthesis at the level of the rate-limiting enzyme, hydroxymethyl glu-taryl coenzyme A reductase (HMG CoA reductase), stimulates cholesterol esterification, and inhibits synthesis of the LDL receptor itself.
Monoclonal antibodies have proven useful in the study of protein structure and in the identification of functional domain of proteins. With the aid of monoclonal antibodies against human LDL, we are trying to identify and eventually purify and characterize the regions of apo B recognized by the LDL receptor. Here we describe seven monoclonal antibodies against LDL which are differentiated on the basis of their cross-reactivities with chemically modified LDL and their abilities to interfere with the LDL pathway. In addition, we describe a novel adaptation of the cotitration method 8 which allows a tentative mapping of the antigenic determinants.
Production of Monoclonal Antibodies
Female 8-week-old BALB/c mice (Jackson Laboratories, Bar Harbor, Maine) whose spleens were to be used for cell fusion were given a primary intraperitoneal injection of 100 fig of LDL in complete Freund's adjuvant (CFA). After 3 weeks, the mice were given a second subcutaneous injection of 50 fig of LDL in CFA. One week later and 3 days before the fusion, 2 fig of LDL was injected intravenously. The technique for cell fusion has been previously described. 10 Following fusion, the cells, suspended in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 15 mM Hepes, 40 fiM 2-mercaptoethanol, penicillin-streptomycin, 30% fetal bovine serum (FBS), 0.11 mM hypoxanthine, 0.38 fiM aminopterine and 16 fiM thymidine were distributed in 576 microculture wells (Costar, Cambridge, Massachusetts). When sufficient growth had occurred, normally at 10 to 15 days, the supernatants were screened by a solid phase radioimmunoassay (RIA) 10 for the presence of anti-LDL antibodies using Removawells (Dynatech Laboratories Incorporated, Dynatech Corporation, Alexandria, Virginia) which had been coated overnight at room temperature with 200 fi\ of a solution of LDL (50 fig LDL protein/ml in 5 mM glycine pH 9.2). The cells in the positive wells were recloned by limiting dilutions in 96 well microculture plates at a cell density that produced growth in approximately 10% of the wells. To identify the immunoglobulin class and subclass, a sample of hybridoma supernatant, concentrated by precipitation with 50% saturated ammonium sulphate was tested by double immunodiffusion against antisera specific for mouse immunoglobulin (Ig) classes and subclasses. 11 Selected subclones were injected intraperitoneally into BALB/c mice (approximately 5 x 10 6 hybridoma cells/mouse) and the resulting ascitic fluid was used as a source of anti-LDL antibodies.
Isolation of Anti-LDL Immunoglobulin
The IgG subclass containing the anti-LDL antibody was isolated from the ascitic fluid of hybridomabearing mice by elution from protein-A Sepharose 4B (Pharmacia Incorporated, Uppsala, Sweden) with a step-wise pH gradient.
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Preparation of Fab Fragments
Papain digestion of isolated IgG was carried out according to the procedures of Gorini et al. 13 The undigested IgG and Fc fragments were removed by passage on Protein-A Sepharose 4B. The anti-LDL activity of the Fab fragments was measured by a solid phase radioimmunoassay. We pipetted 200 (i\ of LDL (50 fig LDL protein/ml in 5 mM glycine pH 9.2) into each Removawell and left it overnight. The following day the wells were washed in 0.15 M NaCI containing 0.025% Tween 20. We then added 200 fi\ aliquots of serial dilutions of anti-LDL Fab in PBS containing 5% FBS to the wells and left them for 3 hours at room temperature. The wells were washed as before and 200 fi\ of purified 125 I antimouse Fab 11 in PBS with 5% FBS was added and kept at room temperature for a further 3 hours. The wells were washed again and the bound radioactivity determined. The concentration of anti-LDL Fab, which resulted in bound radioactivity three times that obtained with an equivalent concentration of normal mouse Fab, was used as a measure of the antibody activity.
Cotltratlon of Anti-LDL Antibodies
The method of Fisher and Brown 8 was modified for soluble antigens and 200 fi\ of LDL (25 fig LDL pro tein/ml in 5mM glycine pH 9.2) was used to coat Removawells as already described. Serial dilutions of either individual antibodies (ascitic fluid) or a 1 to 1 (vol/vol) combination of two different antibodies were prepared in PBS/5% FBS. Then 200 fi\ aliquots of the dilution were added to the Removawells and the rest of the assay was carried out as previously described for measuring antibody activity in the Fab preparations. 14 Free
lodlnatlon of Proteins
125
I was removed by passage on AGIX8 resin (Bio-Rad Laboratories, Richmond, California). Labelled proteins were stored in PBS containing 0.1% bovine serum albumin and 0.02% sodium azide. Immediately after labelling, more than 90% of the radioactivity was precipitated by 10% trichloroacetic acid. In the case of 125 I-LDL, the trichloroacetic acid nonprecipitable radioactivity increased upon storage. Consequently, the 12S I-LDL was repassed on AGIX8 just before an assay and was used within 14 days of the labelling. For binding experiments, LDL were iodinated by the method of Bilheimer et al. 15 
Radioimmunoassay of Apo B
The RIA for apo B was essentially the same as that for apo E. 10 We distributed 200 fi\ of the IgG fraction diluted in 5 mM glycine in Removawells and left it overnight. The concentration of IgG chosen on the basis of preliminary experiments ranged from 5 to 20 /xg/ml depending upon the individual clone. The wells were washed with 0.15 M NaCI with 0.025% Tween 20. The sample to be tested was diluted in PBS containing 5% FBS and mixed with 12S I-LDL; the final concentration of 125 I-LDL was approximately 10 ng/ml. We transferred 200 fi\ of the mixture to the precoated wells and incubated this overnight at room temperature. The wells were washed as before and the bound radioactivity was determined. Under the conditions of the test and in the absence of the unlabelled LDL, 20% of the added radioactivity was bound. The intraassay coefficient of variation was 6%.
Chemical Modification of LDL
Carbamylation, reductive methylation, and cyclohexanedione modification of LDL were carried out as described by Mahley et al 5 and Weisgraber et al. 18 The extent of modification was estimated from the amino acid analysis.
Cyclohexanedione Treatment
We added 12 mg LDL in 1 ml 0.15 M NaCI, 0.01% EDTA (pH 7) to 2 ml 0.15 M cyclohexanedione in 0.2 M sodium borate (pH 8) and incubated this for 2 hours at 35°C. The reaction was terminated by dialysis for 24 hours against 0.15 M NaCI, 0.01% EDTA, pH 7.
Carbamylation
We mixed 2 mg LDL in 1 ml 0.15 M NaCI, 0.01% EDTA (pH 7) with 0.5 ml of 0.2 M sodium borate, pH 8. Then we added 30 mg of sodium cyanate and incubated the mixture for 2 hours at 37°C. The sample was dialyzed for 36 hours against 0.15 M NaCI, 0.01% EDTA, pH 7.
Reductive Methylation
We added 1 mg of sodium borohydride to 2 mg LDL in 1.5 ml 0.2 M sodium borate (pH 8). The reaction was started by the addition of 1 /xl of aqueous formaldehyde (37%); additional 1 /il aliquots were added at 5-minute intervals. At 30 minutes the reaction was terminated by passage on a column of Sephadex G-25 (Pharmacia Incorporated, Uppsala, Sweden). The fractions containing the LDL were pooled and dialyzed against 0.15 M NaCI 0.01% EDTA (pH 7) for 24 hours.
LDL Binding to Human Flbroblasts
Human skin fibroblasts from a forearm skin biopsy and the fibroblast strain GM 1915 (Human Genetic Mutant Cell Repository, Camden, New Jersey) from a homozygous familial hypercholesterolemic (HFH) patient have been characterized previously. 17 For binding experiments, cells were grown in 35 mm dishes (Costar, Cambridge, Massachusetts) containing 2 ml of DMEM supplemented with 10% (vol/vol) FBS. Before reaching confluency, cells were rinsed with 1 ml of sterile PBS and incubated for 48 hours in DMEM containing 10% (vol/vol) lipoprotein-deficient serum (Medium A). Before the experiment, the cells were cooled at 4°C for 30 minutes, Medium A was replaced by 0.7 ml of cold Medium A supplemented with HEPES pH 7.4 and I-LDL were performed as described by Innerarity et al. 18 Specific binding was measured by subtracting the amount of bound 126 I-LDL in the presence of 500 /xg/ml of human LDL. 4 
Determination of the Effect of Antibodies on the LDL-Medlated Suppression of Cholesterol Synthesis
For cholesterol synthesis experiments, cells were plated in 100 mm Petri dishes (Falcon Labware, Oxnard, California) in 10 ml DMEM supplemented with 5% (vol/vol) pooled human serum and 100 units/ml penicillin and streptomycin. After reaching 80% to 90% confluency, the monolayers were rinsed with 5 ml PBS, changed to 10 ml DMEM containing 5% (vol/vol) lipoprotein-deflclent serum (Medium B). 17 After 24 hours of incubation at 37°C, Medium B was removed and replaced by 5 ml of fresh Medium B containing 5 /imol of 14 C-acetate (2 /xCi//imol) (New England Nuclear, Boston, Massachusetts) and either no LDL, 20 /xg/ml LDL (pool of four subjects), or LDL-Fab complexes. After 24 hours the medium was removed, the cells were rinsed twice with 5 ml PBS and were harvested for lipid analysis. For preparation of LDL-Fab complexes, LDL (final concentration 140 fj.g/m\) and Fab fragments at various concentrations were allowed to react in PBS containing 1 mM EDTA for 24 hours at 4°C. LDL Fab complexes were diluted seven times in Medium B and sterilized by ultrafiltration before addition to the cells.
Cholesterol synthesis as measured by 14 C-acetate incorporation into cholesterol was determined by digitonin precipitation 19 of nonsaponifiable lipids as previously described.
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Protein Determination
Protein was measured according to Lowry et al. 20 using bovine serum albumin as a standard.
Results
Cell Fusion
Growth occurred in all wells that were seeded and 47 were positive for anti-apo B. These were recloned by limiting dilution and seven were chosen for detailed study based on their titre. Three hybridomas secreted antibody of the IgGi subclass (1D1, 2D8, 5E11) and four secreted lgG2a antibody (3A8,3A10, 3F5, 4G3). The antibodies showed no reactivity in RIA against apo A-l, apo A-ll, apo C-ll, apo C-lll, or apo E but did react with delipidated denatured apo B.
Cross-Reactivities of Antibodies with Chemically Modified LDL
The cross-reactivities of antibodies with chemically modified antigens provides a method for distinguishing differences in the intramolecular specificities of the antibodies. 21 To detect differences in the Values are means of triplicate determinations ± 1 so. ND = not detected (< 0.5% of the starting reactivity).
specificities of the anti-LDL monoclonal antibodies, we tested chemically modified LDL for its ability to compete with 125 I-LDL in a solid phase RIA. The results from one experiment expressed as the percentage of starting reactivity are shown in table 1. Cyclohexartedlone treatment of LDL, which in this experiment modified 40% of the arginine residues, resulted in a complete loss of reactivity with antibodies 2D8 and 4G3 and a 50% loss of reactivity with 3F5. In contrast, reactivity was increased with 1D1 and unchanged with 3A8, 3A10, and 5E11. Reductive methylation of LDL (60% modification) caused an almost total loss of reactivity with all the antibodies. Carbamylated LDL (12% modification) retained about one-half of its starting reactivity with 1D1, 3A8,3A10,3F5, and 5E11, whereas more than 90% of reactivity with 2D8 and 4G3 was lost. A similar pattern of reactivity was seen in three independent, identical experiments.
Cotitration of Antibodies
Fisher and Brown 8 have recently described a method of cotitration of two monoclonal antibodies to determine if the two monoclonal antibodies react with the same or different antigenic determinants on cell surfaces. We have adapted this technique for soluble antigens. When a solid phase RIA was carried out using increasing dilutions of monoclonal antibodies, the binding curves obtained were characterized by a plateau at low dilutions (figure 1). We observed in preliminary experiments that the height of the plateau was a function of the LDL concentration used to coat the plastic (data not shown). This indicates that, in the plateau region, the LDL is a limiting reactant, a prerequisite for the cotitration experiments. Figure 1 shows an example of the two types of results which were obtained when different antibodies were mixed in a 1 to 1 ratio before being added to the wells. The combination of 3A10 and 3 ) bound in the plateau region of the curve ± 1 SD.
2D8 (figure 1 A) gave a plateau which was significantly higher than that obtained with either of the antibodies individually. This would indicate that 3A10 and 2D8 react with different determinants. The fact that the binding was less than additive may indicate that there are certain steric restrictions on the binding, perhaps at the level of the 12S I rabbit antimouse Fab. In contrast, when the antibodies 3A8 and 3A10 (figure 1 B) were cotitrated, the maximum radioactivity bound was not more than that bound when the two antibodies were titrated separately. This would indicate that the antibodies recognized the same or closely, spatially associated determinants on the LDL. Table 2 summarizes the results of one cotitration experiment. It is clear that the antibodies 1D1 and 2D8 have specificities which are unique. Apparently, 3A8 and 3A10 recognize the same determinant which is probably close to that recognized by 4G3 but distant from the determinant recognized by 3F5. The bound counts obtained with a mixture of 3F5 and 4G3 were not significantly higher than those seen with 4G3 alone. In this experiment, 5E11 seems to have a specificity different from that of the other antibodies. However, in two subsequent experiments, the differences between 5E11, 3A8, and 3A10 were not significant. Otherwise the results from the three experiments were identical.
The Effect of Monoclonal Antibodies on the LDL Pathway
To evaluate the relationship between the determinants recognized by the individual monoclonal antibodies and the site on apo B recognized by the LDL receptor, we tested the ability of their Fab fragments to block 125 I-LDL binding to fibroblasts. The 125 I-LDL concentration (2.5 /xg/ml) was determined to be optimal in preliminary experiments. The Fab fragments were prepared from an IgG preparation from ascitic fluid that contained, in addition to the specific monoclonal antibody, varying amounts of "nonantibody" immunoglobulin; as papain digestion of mouse IgG is associated with a loss in antibody activity, 22 the concentrations of Fab for the binding experiments were chosen on the basis of their respective antibody activities in an RIA against LDL. The most active fragment in RIA, 1D1, Was tested at the equivalent of a 3 M excess relative to apo B (assuming molecular weights of 5 x 10 4 for Fab and 5 x 10 5 for apo B) and the others, at concentrations corresponding to their respective activities in RiA relative to that of 1D1. Under these conditions, the Fab fragments of 3A8, 3A10, 4G3, and 5E11 eliminated virtually all specific binding of 12S l-i_DL, whereas 1D1 and 2D8 had no effect (figure 2). Fab fragments of 3F5 decreased binding by about 65%. When the Fab fragments were tested at a 10-fold higher concentration (a nominative 30 M excess of active Fab fragments relative to apo B), there was no corresponding change in their respective abilities to block LDL binding, indicating that the maximum effect had been reached and that the differences among the antibodies were qualitative (figure 2).
To confirm the results of 125 I-LDL binding studies, we tested the Fab fragments for their ability to interfere with LDL-mediated suppression of cholesterol synthesis in cultured fibroblasts. Incorporation of 14 C-acetate into cholesterol was measured in the absence of exogenous LDL or in the presence of LDL or LDL-Fab complexes as described In the Methods section. The LDL concentration of 20 ptg/ml was determined to be optimal in preliminary experiments. 17 As in the binding experiments, 1D1 was tested at a three-fold and a 30-fold molar excess relative to LDL and the others, at concentrations proportional to their respective activities in RIA relative to 1D1. When tested at a three-fold molar excess, the Fab fragments of 1D1, 2D8, and normal mouse IgG had no effect on the LDL-suppression of cholesterol synthesis ( figure 3 ). In contrast, 3A8, 3A10, 3F5, 4G3, and 5E11 clearly reduced LDL-mediated suppression.
When the Fab fragments were tested at 10-fold higher concentrations, there was no corresponding increase in their abilities to reduce LDL suppression (data not shown). The presence of 20 /ig/ml of exogenous LDL caused a 30% decrease in cholesterol synthesis in HFH fibroblasts (data not shown). This would indicate a significant receptor-independent component of LDL uptake under the conditions of the experiments which could account for the inability of the antibodies to totally eliminate the effects of LDL on cholesterol synthesis. 125 I-LDL was tested at a concentration of 2.5 jug/ml. The protein concentrations of Fab were: 1D1,0.6 /u,g/ml; 2D8,0.8 ju,g/ml; 3A8,3.1 ^g/ml; 3A10,50 /ng/ml; 3F5,2.5 jug/ml; 4G3, 0.3 /ug/ml; and 5E11,1.0 /xg/ml. These represent a nominative three-fold molar excess relative to apo B (open bars). The cross-hatched bars represent the effect of 10-fold higher concentrations of Fab. The data are the means of triplicate dishes ± 1 SD. •Q a u. c Figure 3 . The effect of Fab fragments on suppression of cholesterol synthesis by LDL. The results are expressed as percentages of 14 C-acetate incorporation into cholesterol by cultured human fibrobiasts in the absence of exogenous LDL. The control suppressed state and all Fab fragments were tested in the presence of 20 /ug/ml of LDL. On the basis of their relative activities against LDL in a solid phase RIA, the protein concentrations of Fab used were: 1D1, 5 /xg/ml; 2D8,9.6 /Lig/ml; 3A8,120 /Ltg/ml; 3A10, 5 /xg/ml; 3F5, 50 ju.g/ml; 4G3,15 /u,g/ml; and 5E11, 5 /utg/ ml. Normal mouse Fab (nFab) was tested at a concentration of 50 /xg/ml. The data are the means of triplicate dishes ± 1 SD. The preparation of Fab fragments is different from that in figure 2.
Discussion
We have characterized seven monoclonal antibodies to human apo B with respect to their individual specificities and their capacities to interfere with the inhibition of the LDL pathway.
Several antibodies are distinguished by their characteristic reactions with chemically modified LDL. Most notable are the antibodies 2D8 and 4G3 which show virtually no reactivity with cyclohexanedionetreated LDL. This would suggest that an arginine residue may be present in their respective antigenic determinants or, alternatively, that the conformation of the determinants are altered by modification of arginine residues elsewhere in the molecule. The determinants recognized by 2D8 and 4G3 also appear more susceptible to carbamylation; a reaction which mainly modifies lysine residues. These experiments were designed solely to differentiate among the intramolecular specificities of the antibodies. Any extrapolation of these results to the observation that modification of arginine and lysine residues of LDL eliminated binding to the LDL receptor 5 is not justified at this point.
The cotjtration experiments allowed a further differentiation of the antibody specificities. We propose that the results in table 1 represent three basic types of relationships between individual antibodies. The first type is that in which the two antibodies react with determinants that are far enough apart so that the two antibodies can bind to the same molecule of antigen with little mutual interference. An example of this would be the relationship of 2D8 and 3A10. At the other extreme is the case in which the two antibodies bind to the same antigenic determinant, as would appear to occur with 3A8 and 3A10. The third type of relationship would be that in which the antibodies recognize different antigenic determinants which are either overlapping or close enough together to prevent their mutual binding to the same molecule of antigen. We propose that the relationship of 4G3 to 3A8/3A10 and to 3F5 represents an example of this. While 4G3 cannot be distinguished from either 3A8/3A10 or 3F5, it is clear that 3A8/3A10 and 3F5 bind to different determinants. Thus, the determinant recognized by 4G3 may lie between those recognized by 3A8/3A10 and 3F5 respectively. Interestingly, myoglobin, a molecule of 153 amino acid residues which possesses five antigenic determinants, can fix a maximum of four of the corresponding antibodies at equivalence. 21 With the results in table 1 we have constructed a theoretical "map" of the antigenic determinants as they may be present on apo B (figure 4). Since 2D8 and 1D1 have specificities different from each other and from all the other antibodies, their placement is arbitrary. As antigenic determinants are a function of the three-dimensional structure on the antigen, figure 4 is proposed as a representation of the spatial relationship of the determinants and not necessarily of their positions in the primary amino acid se- quence. Atassi 23 has demonstrated that in lysozyme, spatially adjacent residues that are far apart in the peptide chain can together form an antigenic determinant. Moreover, antigenic determinants tend to be at the surface of the molecule and to occur at bends in the three-dimensional structure. 21 Recently, ContiTronconi et al 24 have used monoclonal antibodies to partially map immunochemically an acetylcholine receptor. They have predicted the relative positions of antigenic determinants from estimations of the composition of antigen-antibody complexes.
When tested in molar excess, Fab fragments of several antibodies were capable both of blocking binding of 126 I-LDL to the LDL receptor and of interfering with the inhibition by LDL of cholesterol synthesis in cultured fibroblasts. These effects were independent of the Fab concentrations from a threefold to a 30-fold molar excess relative to apo B which demonstrate saturation by the antibodies. There is an excellent correlation between the effects of the individual antibodies as shown at two sequential steps in the LDL pathway; this would indicate that the antibodies act by blocking receptor-mediated LDL binding and the subsequent metabolic events in the pathway. The determinants that were grouped together by the cotitration experiments (3F5, 4G3, 3A8, 3A10, and 5E11; see figure 4) are also those that are capable of interference with the LDL pathway. This would suggest that the site on apo B recognized by the LDL receptor is in this region of the molecule. The fact that 3F5 is intermediate in its ability to block both LDL binding and LDL-mediated suppression of cholesterol synthesis compared to the other antibodies may be a reflection of its relative distance from the actual binding site.
Due to its insolubility and its large size, apo B has remained poorly characterized. With the aid of monoclonal antibodies against LDL, we have succeeded in differentiating a series of distinct antigenic determinants on apo B and have presented a tentative map of these determinants as they may appear in LDL. A number of the determinants appear to be situated in the region of apo B recognized by the LDL receptor. This theoretical map is designed to serve as a working model and will no doubt be changed and expanded as other monoclonal antibodies are characterized and as the reactivities of the antibodies with proteolytic fragments of apo B are determined. Monoclonal antibodies offer a promising new approach to the mapping of functional domains on LDL and to the determination of the structure of apo B.
